← Back to Patent Explorer
US5236928A Expired / Lapsed US ⏱️ 0.0 years remaining

Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists

Assignee: Merck and Co Inc
•
Filing: 1992-05-29
•
Granted: 1993-08-17
•
Expires: 2012-05-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There are disclosed substituted imidazole derivatives of Formula I bearing acidic functional groups which are useful as angiotensin II antagonists. <IMAGE> I

Inventors

  • 👤 Prasun K. Chakravarty
  • 👤 William J. Greenlee
  • 👤 Arthur A. Patchett

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 12:54
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/10; C07D233/00; C07D233/54; C07D233/66; C07D233/84; C07D233/90; C07D403/12; C07D403/14; C07D413/00; C07D413/02; C07D413/10

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 1274 words
A compound of structural formula I ##STR46## or a pharmaceutically acceptable salt thereof wherein: R 1 is (a) --CO 2 R 10 , (b) --NHSO 2 R 12 , (c) --SO 2 NHR 12 , ##STR47## (g) --CONHNHSO 2 CF 3 , (h) --CH 2 SO 2 NHR 12 , (i) --SO 2 NHCOR 12 , (j) --CH 2 SO 2 NHCOR 12 , (k) --CONHSO 2 R 12 , (l) --CH 2 CONHSO 2 R 12 , (m) --NHSO 2 NHCOR 12 , (n) --NHCONHSO 2 R 12 , (o) --SO 2 NHCONR 2a R 12 , or (p) --CONHSO 2 NR 2a R 12 ; R 2 is: (a) H, or (b) (C 1 -C 6 )-alkyl; R 2a is: (a) R 2 , (b) --CH 2 -aryl, wherein aryl is phenyl or naphthyl unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of: i) Cl, Br, I, F, ii) (C 1 -C 4 )-alkyl, iii) (C 1 -C 4 )-alkoxy, iv) NO 2 , v) CF 3 , vi) (C 1 -C 4 )-alkylthio, vii) hydroxy, viii) amino, ix) (C 3 -C 7 )-cycloalkyl, x) (C 3 -C 10 )-alkenyl, or xi) CN, or (c) aryl as defined in R 2a (b) above; R 3 is: (a) --SO 2 NHR 12 , (b) --CH 2 SO 2 NHR 12 , (c) --SO 2 NHCOR 12 , (d) --CH 2 SO 2 NHCOR 12 , (e) --CONHSO 2 R 12 , (f) --CH 2 CONHSO 2 R 12 , (g) --NHSO 2 NHCOR 12 , (h) --NHCONHSO 2 R 12 , (i) --SO 2 NHCONR 2a R 12 , (j) --CONHSO 2 NR 2a R 12 , or (k) --NHSO 2 R 12 ; y is 0 or 1; R 4 is: (a) H, (b) (C 1 -C 8 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, (c) Cl, Br, I, F, (d) NO 2 , (e) (C 1 -C 8 )-perfluoroalkyl, (f) (C 1 -C 8 )-perfluoroalkenyl, (g) pentafluorophenyl, (h) CN, (i) phenyl, (j) phenyl-(C 1 -C 3 )-alkyl, (k) phenyl and phenyl-(C 1 -C 3 )-alkyl substituted on the phenyl ring with one or two substituents selected from: i) (C 1 -C 4 )-alkyl, ii) (C 1 -C 4 )-alkoxy, iii) F, Cl, Br, I, iv) hydroxy, v) CF 3 , vi) CO 2 R 2a , vii) NO 2 , or viii) SO 2 NR 2a R 2a ; (1) phenyl-(C 2 -C 6 )-alkenyl, ##STR48## (n) --(CH 2 ) n --S(O) x R 15 , ##STR49## (u) --(CH 2 ) n --NHSO 2 R 16 , or (v) --(CH 2 ) n --F; R 5 is: (a) (C 1 -C 9 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl each of which is unsubstituted or substituted with a substituent selected from the group consisting of: i) aryl as defined in R 2a (b) above, ii) (C 3 -C 7 )-cycloalkyl, iii) Cl, Br, I, F, iv) COOR 2 , vii) N((C 1 -C 4 )-alkyl) 2 , viii) NHSO 2 R 2 , ix) CF 3 , x) COOR 2 , or xi) SO 2 NHR 2a , (b) aryl, or (d) (C 1 -C 4 )-perfluoroalkyl; B is a single bond; x is 0 to 2; s is 0 to 5; m is 1 to 5; p is 0 to 3; n is 1 to 10; R 6 is: (a) H, (b) Cl, Br, I, F, (c) (C 1 -C 6 )-alkyl, (d) (C 1 -C 6 )-alkoxy, or (e) (C 1 -C 6 )-alkoxyalkyl; R 7 is: (a) H, (b) Cl, Br, I, F, (c) NO 2 , (d) (C 1 -C 6 )-alkyl, (e) (C 1 -C 6 )-acyloxy, (f) (C 3 -C 6 )-cycloalkyl, (g) (C 1 -C 6 )-alkoxy, (h) --NHSO 2 R 2a , (i) hydroxy (C 1 -C 4 )-alkyl, (j) (C 1 -C 4 )-alkyl-aryl, (k) aryl-(C 1 -C 4 )-alkyl, (l) (C 1 -C 4 )-alkylthio, (m) (C 1 -C 4 )-alkylsulfinyl, (n) (C 1 -C 4 )-alkylsulfonyl, (o) NH 2 , (p) NH((C 1 -C 4 )-alkyl), (q) NH((C 1 -C 4 )-alkyl) 2 , (r) (C 1 -C 4 )-fluoroalkyl, (s) --SO 2 --NHR 10 , (t) aryl, (u) furyl, or (v) --COOR 11 ; R 8 and R 9 are independently: H, Cl, Br, I, F, --NO 2 , --NH 2 , NH((C 1 -C 4 )-alkyl), N((C 1 -C 4 ) alkyl) 2 , --SO 2 NHR 10 , CF 3 , (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl or when R 8 and R 9 are on adjacent carbon atoms, they are joined to form an aryl ring; R 10 is: H, (C 1 -C 5 )-alkyl, aryl or --CH 2 -aryl, wherein aryl is as defined in R 2a (b); R 11 is ##STR50## R 12 is: (a) aryl as defined in R 2a (b), (b) heteroaryl, wherein heteroaryl is defined as an unsubstituted, monosubstituted or disubstituted hetero aromatic ring selected from the group consisting of: isoxazolyl, and pyrimidyl, wherein the substituents are members selected from the group consisting of: --OH, --SH, --(C 1 -C 4 )-alkyl, --(C 1 -C 4 )-alkoxy, --CF 3 , Cl, Br, F, I, --NO 2 , --CO 2 H, --CO 2 --(C 1 -C 4 )-alkyl, --NH 2 , --NH((C 1 -C 4 )-alkyl), or --N((C 1 -C 4 )-alkyl) 2 , (c) (C 3 -C 4 )-cycloalkyl, (d) (C 1 -C 4 )-alkyl which is unsubstituted or substituted with a substituent selected from the group consisting of: aryl as defined in R 2a (b), heteroaryl as defined above in R 12 (b), --OH, --SH, (C 1 -C 4 )-alkyl, --O--(C 1 -C 4 )-alkyl --S(O) x --(C 1 -C 4 )-alkyl, --CF 3 , Cl, Br, F, I, --NO 2 , --CO 2 H, --CO 2 --(C 1 -C 4 )-alkyl, --NH 2 , --NH[(C 1 -C 4 )-alkyl], --NHCOR 2a , or --N[(C 1 -C 4 )-alkyl] 2 , or (e) (C 1 -C 4 )-perfluoroalkyl; R 13 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) aryl as defined in R 2a (b), (d) aryl-(C 1 -C 6 )-alkyl-(C═O)--, wherein aryl is as defined in R 2a (b), (e) (C 1 -C 6 )-alkyl-(C═O)--, (f) (C 3 -C 6 )-cycloalkyl, or (g) allyl; R 14 is: (a) H, (b) (C 1 -C 8 )-alkyl, (c) phenyl, or (d) benzyl; R 15 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, (d) --(CH 2 ) p -phenyl, (e) --OR 17 , (f) morpholin-4-yl, or (g) --NR 18 R 19 ; R 16 is: (a) (C 1 -C 8 )-alkyl, (b) (C 1 -C 8 )-perfluoroalkyl, (c) 1-adamantyl, (d) 1-naphthyl, (e) (1-naphthyl)ethyl, or (f) --(CH 2 ) p -phenyl; R 17 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, (d) phenyl, or (e) benzyl; R 18 and R 19 are independently: (a) H, (b) (C 1 -C 4 )-alkyl, (c) phenyl, (d) benzyl, or (e) α-methylbenzyl; R 20 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, or (d) --CH 2 -aryl; R 21 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 2 -C 4 )-alkenyl, or (d) (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl; R 22 is: (a) CN, (b) NO 2 , or (c) COOR 10 ; and X is a carbon-carbon single bond.
Claim 2
Dependent Claim 1274 words
A compound of structural formula I ##STR46## or a pharmaceutically acceptable salt thereof wherein: R 1 is (a) --CO 2 R 10 , (b) --NHSO 2 R 12 , (c) --SO 2 NHR 12 , ##STR47## (g) --CONHNHSO 2 CF 3 , (h) --CH 2 SO 2 NHR 12 , (i) --SO 2 NHCOR 12 , (j) --CH 2 SO 2 NHCOR 12 , (k) --CONHSO 2 R 12 , (l) --CH 2 CONHSO 2 R 12 , (m) --NHSO 2 NHCOR 12 , (n) --NHCONHSO 2 R 12 , (o) --SO 2 NHCONR 2a R 12 , or (p) --CONHSO 2 NR 2a R 12 ; R 2 is: (a) H, or (b) (C 1 -C 6 )-alkyl; R 2a is: (a) R 2 , (b) --CH 2 -aryl, wherein aryl is phenyl or naphthyl unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of: i) Cl, Br, I, F, ii) (C 1 -C 4 )-alkyl, iii) (C 1 -C 4 )-alkoxy, iv) NO 2 , v) CF 3 , vi) (C 1 -C 4 )-alkylthio, vii) hydroxy, viii) amino, ix) (C 3 -C 7 )-cycloalkyl, x) (C 3 -C 10 )-alkenyl, or xi) CN, or (c) aryl as defined in R 2a (b) above; R 3 is: (a) --SO 2 NHR 12 , (b) --CH 2 SO 2 NHR 12 , (c) --SO 2 NHCOR 12 , (d) --CH 2 SO 2 NHCOR 12 , (e) --CONHSO 2 R 12 , (f) --CH 2 CONHSO 2 R 12 , (g) --NHSO 2 NHCOR 12 , (h) --NHCONHSO 2 R 12 , (i) --SO 2 NHCONR 2a R 12 , (j) --CONHSO 2 NR 2a R 12 , or (k) --NHSO 2 R 12 ; y is 0 or 1; R 4 is: (a) H, (b) (C 1 -C 8 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, (c) Cl, Br, I, F, (d) NO 2 , (e) (C 1 -C 8 )-perfluoroalkyl, (f) (C 1 -C 8 )-perfluoroalkenyl, (g) pentafluorophenyl, (h) CN, (i) phenyl, (j) phenyl-(C 1 -C 3 )-alkyl, (k) phenyl and phenyl-(C 1 -C 3 )-alkyl substituted on the phenyl ring with one or two substituents selected from: i) (C 1 -C 4 )-alkyl, ii) (C 1 -C 4 )-alkoxy, iii) F, Cl, Br, I, iv) hydroxy, v) CF 3 , vi) CO 2 R 2a , vii) NO 2 , or viii) SO 2 NR 2a R 2a ; (1) phenyl-(C 2 -C 6 )-alkenyl, ##STR48## (n) --(CH 2 ) n --S(O) x R 15 , ##STR49## (u) --(CH 2 ) n --NHSO 2 R 16 , or (v) --(CH 2 ) n --F; R 5 is: (a) (C 1 -C 9 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl each of which is unsubstituted or substituted with a substituent selected from the group consisting of: i) aryl as defined in R 2a (b) above, ii) (C 3 -C 7 )-cycloalkyl, iii) Cl, Br, I, F, iv) COOR 2 , vii) N((C 1 -C 4 )-alkyl) 2 , viii) NHSO 2 R 2 , ix) CF 3 , x) COOR 2 , or xi) SO 2 NHR 2a , (b) aryl, or (d) (C 1 -C 4 )-perfluoroalkyl; B is a single bond; x is 0 to 2; s is 0 to 5; m is 1 to 5; p is 0 to 3; n is 1 to 10; R 6 is: (a) H, (b) Cl, Br, I, F, (c) (C 1 -C 6 )-alkyl, (d) (C 1 -C 6 )-alkoxy, or (e) (C 1 -C 6 )-alkoxyalkyl; R 7 is: (a) H, (b) Cl, Br, I, F, (c) NO 2 , (d) (C 1 -C 6 )-alkyl, (e) (C 1 -C 6 )-acyloxy, (f) (C 3 -C 6 )-cycloalkyl, (g) (C 1 -C 6 )-alkoxy, (h) --NHSO 2 R 2a , (i) hydroxy (C 1 -C 4 )-alkyl, (j) (C 1 -C 4 )-alkyl-aryl, (k) aryl-(C 1 -C 4 )-alkyl, (l) (C 1 -C 4 )-alkylthio, (m) (C 1 -C 4 )-alkylsulfinyl, (n) (C 1 -C 4 )-alkylsulfonyl, (o) NH 2 , (p) NH((C 1 -C 4 )-alkyl), (q) NH((C 1 -C 4 )-alkyl) 2 , (r) (C 1 -C 4 )-fluoroalkyl, (s) --SO 2 --NHR 10 , (t) aryl, (u) furyl, or (v) --COOR 11 ; R 8 and R 9 are independently: H, Cl, Br, I, F, --NO 2 , --NH 2 , NH((C 1 -C 4 )-alkyl), N((C 1 -C 4 ) alkyl) 2 , --SO 2 NHR 10 , CF 3 , (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl or when R 8 and R 9 are on adjacent carbon atoms, they are joined to form an aryl ring; R 10 is: H, (C 1 -C 5 )-alkyl, aryl or --CH 2 -aryl, wherein aryl is as defined in R 2a (b); R 11 is ##STR50## R 12 is: (a) aryl as defined in R 2a (b), (b) heteroaryl, wherein heteroaryl is defined as an unsubstituted, monosubstituted or disubstituted hetero aromatic ring selected from the group consisting of: isoxazolyl, and pyrimidyl, wherein the substituents are members selected from the group consisting of: --OH, --SH, --(C 1 -C 4 )-alkyl, --(C 1 -C 4 )-alkoxy, --CF 3 , Cl, Br, F, I, --NO 2 , --CO 2 H, --CO 2 --(C 1 -C 4 )-alkyl, --NH 2 , --NH((C 1 -C 4 )-alkyl), or --N((C 1 -C 4 )-alkyl) 2 , (c) (C 3 -C 4 )-cycloalkyl, (d) (C 1 -C 4 )-alkyl which is unsubstituted or substituted with a substituent selected from the group consisting of: aryl as defined in R 2a (b), heteroaryl as defined above in R 12 (b), --OH, --SH, (C 1 -C 4 )-alkyl, --O--(C 1 -C 4 )-alkyl --S(O) x --(C 1 -C 4 )-alkyl, --CF 3 , Cl, Br, F, I, --NO 2 , --CO 2 H, --CO 2 --(C 1 -C 4 )-alkyl, --NH 2 , --NH[(C 1 -C 4 )-alkyl], --NHCOR 2a , or --N[(C 1 -C 4 )-alkyl] 2 , or (e) (C 1 -C 4 )-perfluoroalkyl; R 13 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) aryl as defined in R 2a (b), (d) aryl-(C 1 -C 6 )-alkyl-(C═O)--, wherein aryl is as defined in R 2a (b), (e) (C 1 -C 6 )-alkyl-(C═O)--, (f) (C 3 -C 6 )-cycloalkyl, or (g) allyl; R 14 is: (a) H, (b) (C 1 -C 8 )-alkyl, (c) phenyl, or (d) benzyl; R 15 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, (d) --(CH 2 ) p -phenyl, (e) --OR 17 , (f) morpholin-4-yl, or (g) --NR 18 R 19 ; R 16 is: (a) (C 1 -C 8 )-alkyl, (b) (C 1 -C 8 )-perfluoroalkyl, (c) 1-adamantyl, (d) 1-naphthyl, (e) (1-naphthyl)ethyl, or (f) --(CH 2 ) p -phenyl; R 17 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, (d) phenyl, or (e) benzyl; R 18 and R 19 are independently: (a) H, (b) (C 1 -C 4 )-alkyl, (c) phenyl, (d) benzyl, or (e) α-methylbenzyl; R 20 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 3 -C 6 )-cycloalkyl, or (d) --CH 2 -aryl; R 21 is: (a) H, (b) (C 1 -C 6 )-alkyl, (c) (C 2 -C 4 )-alkenyl, or (d) (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl; R 22 is: (a) CN, (b) NO 2 , or (c) COOR 10 ; and X is a carbon-carbon single bond.
Claim 3
Dependent Claim 225 words
A compound of structural formula ##STR51## or its pharmaceutically acceptable salt, wherein the compound is selected from the group consisting of: __________________________________________________________________________ R.sup.1 R.sup.3 R.sup.4 R.sup.5 __________________________________________________________________________ SO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR52## CONHSO.sub.2 Ph Cl n-butyl SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 CONHSO.sub.2 Ph Cl n-butyl SO.sub.2 NHCO(CH.sub.2).sub.4 COOEt CONHSO.sub.2 Ph Cl n-butyl ##STR53## CONHSO.sub.2 Ph Cl n-butyl ##STR54## CONHSO.sub.2 Ph Cl n-butyl ##STR55## CONHSO.sub.2 Ph Cl n-butyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR56## CONHSO.sub.2 Ph Cl n-butyl ##STR57## CONHSO.sub.2 Ph Cl n-butyl ##STR58## CONHSO.sub.2 Ph Cl n-butyl ##STR59## CONHSO.sub.2 Ph Cl n-butyl ##STR60## CONHSO.sub.2 Ph Cl n-butyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR61## CONHSO.sub.2 Ph Cl n-butyl ##STR62## CONHSO.sub.2 Ph Cl n-butyl ##STR63## CONHSO.sub.2 Ph Cl n-butyl COOH CONHSO.sub.2 Ph Cl n-butyl tetrazol-5-yl CONHSO.sub.2 Ph Cl n-butyl tetrazol-5-yl SO.sub.2 NHCOPh Cl n-butyl tetrazol-5-yl ##STR64## Cl n-propyl ##STR65## SO.sub.2 NHCOPh ethyl n-propyl tetrazol-5-yl ##STR66## ethyl n-propyl tetrazol-5-yl ##STR67## ethyl n-propyl SO.sub.2 NHCOPh ##STR68## ethyl n-propyl ##STR69## SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 ethyl n-propyl ##STR70## SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 H n-propyl SO.sub.2 NHCOPh SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 H n-butyl SO.sub.2 NHCOPh CONHSO.sub.2 Ph ethyl n-propyl SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 COOCH.sub.2 OC(O)CH.sub.3 ethyl n-propyl tetrazol-5-yl ##STR71## Cl n-butyl tetrazol-5-yl ##STR72## H n-butyl tetrazol-5-yl ##STR73## Cl n-propyl SO.sub.2 NHCOPh ##STR74## Cl n-propyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-propyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph ethyl n-propyl SO.sub.2 NHCOPh SO.sub.2 NHCOPh CF.sub.2 CF.sub.3 n-propyl __________________________________________________________________________
Claim 4
Dependent Claim 225 words
A compound of structural formula ##STR51## or its pharmaceutically acceptable salt, wherein the compound is selected from the group consisting of: __________________________________________________________________________ R.sup.1 R.sup.3 R.sup.4 R.sup.5 __________________________________________________________________________ SO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR52## CONHSO.sub.2 Ph Cl n-butyl SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 CONHSO.sub.2 Ph Cl n-butyl SO.sub.2 NHCO(CH.sub.2).sub.4 COOEt CONHSO.sub.2 Ph Cl n-butyl ##STR53## CONHSO.sub.2 Ph Cl n-butyl ##STR54## CONHSO.sub.2 Ph Cl n-butyl ##STR55## CONHSO.sub.2 Ph Cl n-butyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR56## CONHSO.sub.2 Ph Cl n-butyl ##STR57## CONHSO.sub.2 Ph Cl n-butyl ##STR58## CONHSO.sub.2 Ph Cl n-butyl ##STR59## CONHSO.sub.2 Ph Cl n-butyl ##STR60## CONHSO.sub.2 Ph Cl n-butyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-butyl ##STR61## CONHSO.sub.2 Ph Cl n-butyl ##STR62## CONHSO.sub.2 Ph Cl n-butyl ##STR63## CONHSO.sub.2 Ph Cl n-butyl COOH CONHSO.sub.2 Ph Cl n-butyl tetrazol-5-yl CONHSO.sub.2 Ph Cl n-butyl tetrazol-5-yl SO.sub.2 NHCOPh Cl n-butyl tetrazol-5-yl ##STR64## Cl n-propyl ##STR65## SO.sub.2 NHCOPh ethyl n-propyl tetrazol-5-yl ##STR66## ethyl n-propyl tetrazol-5-yl ##STR67## ethyl n-propyl SO.sub.2 NHCOPh ##STR68## ethyl n-propyl ##STR69## SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 ethyl n-propyl ##STR70## SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 H n-propyl SO.sub.2 NHCOPh SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 H n-butyl SO.sub.2 NHCOPh CONHSO.sub.2 Ph ethyl n-propyl SO.sub.2 NHCO(CH.sub.2).sub.5 NH.sub.2 COOCH.sub.2 OC(O)CH.sub.3 ethyl n-propyl tetrazol-5-yl ##STR71## Cl n-butyl tetrazol-5-yl ##STR72## H n-butyl tetrazol-5-yl ##STR73## Cl n-propyl SO.sub.2 NHCOPh ##STR74## Cl n-propyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph Cl n-propyl NHSO.sub.2 NHCOPh CONHSO.sub.2 Ph ethyl n-propyl SO.sub.2 NHCOPh SO.sub.2 NHCOPh CF.sub.2 CF.sub.3 n-propyl __________________________________________________________________________
Claim 5
Dependent Claim 26 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.
Claim 6
Dependent Claim 26 words
A method of treating hypertension which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1.
Claim 7
Dependent Claim 26 words
An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically acceptable carrier and an effective ocular antihypertensive amount of a compound of claim 1.
Claim 8
Dependent Claim 27 words
A method of treating ocular hypertension comprising administering to a patient in need of such treatment an effective ocular antihypertensive amount of a compound of claim 1.
Claim 9
Dependent Claim 29 words
A method of treating cognitive dysfunction, anxiety, or depression comprising administering to a patient in need of such treatment, a therapeutically effective amount of a compound of claim 1.
Claim 10
Dependent Claim 384 words
A compound of claim 1 or a pharmaceutically acceptable salt wherein: R 1 is (a) --CO 2 R 10 , (b) --NHSO 2 R 12 , (c) --SO 2 NHR 12 , ##STR75## (g) --CONHNHSO 2 CF 3 , (h) --CH 2 SO 2 NHR 12 , (i) --SO 2 NHCOR 12 , (j) --CH 2 SO 2 NHCOR 12 , (k) --CONHSO 2 R 12 , (l) --CH 2 CONHSO 2 R 12 , (m) --NHSO 2 NHCOR 12 , (n) --NHCONHSO 2 R 12 , (o) --SO 2 NHCONR 2a R 12 , or (p) --CONHSO 2 NR 2a R 12 ; R 3 is: (a) --SO 2 NHR 12 , (b) --CH 2 SO 2 NHR 12 , (c) --SO 2 NHCOR 12 , (d) --CH 2 SO 2 NHCOR 12 , (e) --CONHSO 2 R 12 , (f) --CH 2 CONHSO 2 R 12 , (g) --NHSO 2 NHCOR 12 , or (h) --NHCONHSO 2 R 12 ; B is: a single bond; R 4 is: (a) H, (b) (C 1 -C 8 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, (c) Cl, Br, I, F, (d) NO 2 , (e) (C 1 -C 8 )-perfluoroalkyl, (f) (C 1 -C 8 )-perfluoroalkenyl, (g) pentafluorophenyl, (h) CN, (i) phenyl, (j) phenyl-(C 1 -C 3 )-alkyl, (k) phenyl and phenyl-(C 1 -C 3 )-alkyl substituted on the phenyl ring with one or two substituents selected from the group consisting of: i) (C 1 -C 4 )-alkyl, ii) (C 1 -C 4 )-alkoxy, iii) F, Cl, Br, I, iv) hydroxy, v) CF 3 , vi) CO 2 R 2a , vii) NO 2 , and viii) SO 2 NR 2a R 2a ; (l) phenyl-(C 2 -C 6 )-alkenyl, ##STR76## (n) --(CH 2 ) n --SO 2 R 15 , wherein n is 0-4, ##STR77## R 5 is: (a) (C 1 -C 9 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl each of which is unsubstituted or substituted with a substituent selected from the group consisting of: i) aryl as defined in R 2a (b), ii) (C 3 -C 7 )-cycloalkyl, iii) Cl, Br, I, F, and iv) CF 3 , or (b) (C 1 -C 4 )-perfluoroalkyl; and x is: a carbon-carbon single bond.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-08-16 1997-02-15 1997-08-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-08-16 2001-02-15 2001-08-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-08-16 2005-02-15 2005-08-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag